Turn's GX-03 shows significant disease reduction in peer-reviewed preclinical data
TTRX has more than doubled off its 52-week low of $2.57 on elevated volume (2.0× avg).
Summary
Turn Therapeutics announced positive peer-reviewed preclinical data for its drug candidate GX-03, demonstrating a statistically significant reduction in disease severity in an IL-36 associated murine dermatitis model. This news follows an 8-K filed earlier today regarding the publication. The positive data provides further scientific validation for GX-03, which is currently in a Phase 2 trial. Topline results from the Phase 2 trial are expected mid-2026, which will be a key event to watch.
At the time of this announcement, TTRX was trading at $5.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $159.7M. The 52-week trading range was $2.57 to $26.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.